retatrutide clinical trial results Triple hormone receptor agonist for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a Lilly's triple agonist achieves 16.8%

The literature study demonstrates the utilization of botanical and plant-derived treatments for the management of type 2 diabetes mellitus

Published in the New England Journal of Medicine, the trial tested retatrutide at doses of 1mg, 4mg, 8mg, and 12mg against placebo over 48 weeks

Your GP is the natural first point of contact and can assess your overall health, calculate your BMI, review any relevant comorbidities, and determine whether you meet the criteria for approved weight management treatments on the NHS or via a referral to a specialist service

I no longer have any affiliation with the bank and therefore I aim to derive a facts-based analysis, whilst any views expressed here do not represent investment advice or the views of my former employer

82.0% of the patients were being treated with metformin HCl, 40.9% with insulin, 42.7% with a sulfonylurea, 16.8% with a DPP4 inhibitor, and 4.4% with a GLP-1 receptor agonist

Since then, it has become one of the UKs most popular peptide products, with over 10,000 units sold